SCHEMBL11355286

SCHEMBL11355286

O=C1c2ccccc2CN1N1CCCCC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.69
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
PKM P14618 3/20 0.42
KDM4E B2RXH2 2/20 0.41
ALOX15 P16050 2/20 0.41
TSHR P16473 2/20 0.41
SIRT1 Q96EB6 1/20 0.41
CYP2A6 P11509 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
ALDH1A1 P00352 2/20 0.40
METAP1 P53582 2/20 0.40
HTT P42858 1/20 0.40
XIAP P98170 1/20 0.40
HKDC1 Q2TB90 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CYP11B2 P19099 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2352069 0.83 KMT2A (0.65) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL14352086 0.83 KMT2A (0.65) KMT2ANPC1RAB9APKMKDM4E
Diftalone SCHEMBL29644941 0.82 KMT2A (1.00) KMT2ANPC1RAB9APKMKDM4E
Diftalone SCHEMBL35351 0.82 KMT2A (1.00) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL2343942 0.79 KMT2A (0.59) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL23832541 0.74 KMT2A (0.67) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL29569183 0.74 KMT2A (0.67) KMT2ANPC1RAB9APKMKDM4E
Diftalone SCHEMBL8196066 0.73 KMT2A (0.78) KMT2ANPC1RAB9APKMKDM4E
Hydrochloric Acid SCHEMBL4557636 0.72 KMT2A (0.65) KMT2ANPC1RAB9APKMKDM4E
Diftalone SCHEMBL28198200 0.71 KMT2A (0.75) KMT2ANPC1RAB9APKMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376094-A2 SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE LES LABORATOIRES SERVIER (FR) 2024-11-14 US disclosed
US-20240182464-A1 SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE Les Laboratoirens Serviece (FR) 2024-06-06 US disclosed
CN-117794929-A Selective BCL-XL PROTAC compounds and methods of use 法国施维雅药厂 2024-03-29 CN disclosed
WO-2024017392-A1 PYRIMIDINE RING COMPOUND, INTERMEDIATE THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 上海医药集团股份有限公司 2024-01-25 WO disclosed
WO-2023241598-A1 AROMATIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF IN PREPARATION OF ESTROGEN RECEPTOR DEGRADER 海创药业股份有限公司 2023-12-21 WO disclosed
EP-4288434-A1 SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE Les Laboratoires Servier (FR) 2023-12-13 EP disclosed
US-4255429-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1981-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182464-A1 SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE CRBN, XIAP, BCL2L11 KMT2A 836/4885NPC1 3544/4885RAB9A 2737/4885
US-20240376094-A2 SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE CRBN, XIAP, BCL2L11 KMT2A 836/4885NPC1 3544/4885RAB9A 2737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.